Boehringer/Medivir: Filling Gaps, Spreading Risk

Boehringer Ingelheim's generous deal with Medivir for the Swedish group's Phase II HIV compound reflects Boehringer's need to fill a gap in its HIV portfolio. It's also the latest illustration of Medivir's growing deal making wisdom. The biotech spreads risk through adding a third HIV licensing partner alongside Roche and GSK. And by holding on to Nordic marketing rights, Medivir is more likely to stay involved in development decisions.

"Companies will pay a lot for an HIV compound that complements what they already have in their portfolio," observed Medivir AB 's VP, Pharmaceutical Development Johan Harmenberg, MD, PhD, during an interview in June 2003. He had some reason for confidence: his firm was, at the time, in discussions with Boehringer Ingelheim GMBH on its Phase II HIV candidate, alovudine, the Swedish biotech's only un-partnered HIV compound. Without a nucleoside reverse transcriptase inhibitor (NRTI) like alovudine, Boehringer's own one-product franchise was at a distinct disadvantage to competitors whose multi-drug/multi-action portfolios could address viral resistance in ways Boehringer simply couldn't.

NRTIs such as GlaxoSmithKline PLC's zidovudine (Retrovir/AZT) and lamivudine (Epivir) are just one class of drugs used to fight HIV....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.